Mounjaro Side Effects: Complete FDA Safety Guide
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. The most common side effects are gastrointestinal, nausea, diarrhoea, decreased appetite, vomiting, constipation, and the most serious are pancreatitis, gallbladder disease, kidney injury, hypoglycaemia with insulin or sulfonylureas, and a boxed warning about thyroid C-cell tumours.
Mounjaro (Tirzepatide) is approved as a Dual GIP/GLP-1 receptor agonist. Most common side effects are gastrointestinal (nausea, vomiting, diarrhoea, constipation). Serious risks include pancreatitis, kidney injury, gallbladder disease and hypoglycaemia with insulin. It carries an FDA boxed warning for thyroid C-cell tumours.
Key Takeaways
- Mounjaro carries a boxed warning for thyroid C-cell tumours, contraindicated if personal or family history of medullary thyroid carcinoma or MEN2.
- The most common side effects are GI: nausea, diarrhoea, decreased appetite, vomiting, constipation, abdominal pain.
- Serious risks listed on the label: pancreatitis, acute kidney injury, gallbladder disease, severe hypoglycaemia with insulin/sulfonylureas, diabetic retinopathy worsening, hypersensitivity reactions.
- Alcohol is not a direct interaction but compounds GI symptoms and hypoglycaemia, read more.
- Disclose Mounjaro use to your anaesthetist before any procedure due to delayed gastric emptying and aspiration risk.
- Check Mounjaro against your full medication list with the Allmeds drug interaction checker.
What is Mounjaro, and what is it used for?
Mounjaro is a once-weekly injectable tirzepatide approved for type 2 diabetes. Zepbound is the same molecule approved for chronic weight management.
| Property | Detail |
|---|---|
| Generic name | Tirzepatide |
| Brand names | Mounjaro (T2D), Zepbound (weight management) |
| Drug class | Dual GIP / GLP-1 receptor agonist |
| FDA approval status | Approved, type 2 diabetes (Mounjaro), chronic weight management (Zepbound) |
| Route | Subcutaneous injection, once weekly |
| Boxed warning | Thyroid C-cell tumours (animal data) |
| Common GI side effects | Nausea, diarrhoea, vomiting, decreased appetite, constipation, abdominal pain |
| Major label warnings | Pancreatitis, kidney injury, gallbladder disease, hypoglycaemia, retinopathy |
What are the side effects of Mounjaro?
The FDA prescribing information for Mounjaro groups side effects into common gastrointestinal symptoms (very frequent at initiation and dose escalation) and serious warnings (less frequent but clinically important). The table below summarises the labelled categories with severity colour-coding.
| Side Effect Category | What May Occur | Why It Matters |
|---|---|---|
| Pancreatitis | Severe, persistent abdominal pain (sometimes radiating to the back), nausea, vomiting | All GLP-1 labels warn about acute pancreatitis. Stop the medicine and seek urgent assessment. |
| Thyroid C-cell tumours (boxed warning) | Neck mass, hoarseness, difficulty swallowing, persistent neck pain | Animal studies show medullary thyroid carcinoma risk. Contraindicated if personal or family history of MTC or MEN2. |
| Acute kidney injury | Reduced urine output, swelling, fatigue, usually after vomiting or diarrhoea | Dehydration from GI side effects can precipitate AKI, particularly in patients with prior renal disease. |
| Severe hypoglycaemia | Sweating, shakiness, confusion, palpitations, seizure, loss of consciousness | Risk rises sharply when combined with insulin or sulfonylureas. Dose reduction of the other glucose-lowering drug is usually required. |
| Gallbladder disease | Right-upper abdominal pain, fever, jaundice | Cholelithiasis and cholecystitis are reported, especially with rapid weight loss. |
| Severe gastrointestinal reactions | Persistent nausea, vomiting, diarrhoea, constipation, abdominal pain | Common and dose-dependent. Most pronounced during initiation and dose escalation. |
| Diabetic retinopathy worsening | Blurred vision, vision changes | Rapid glucose lowering has been associated with transient worsening, relevant in long-standing type 2 diabetes. |
| Hypersensitivity reactions | Rash, urticaria, angioedema, anaphylaxis | Stop the medicine and seek urgent care for serious allergic features. |
| Injection-site reactions | Redness, swelling, itching, induration at the injection site | Usually mild; persistent reactions warrant clinical review. |
| Aspiration risk during anaesthesia | Delayed gastric emptying may leave food in the stomach during sedation | Disclose GLP-1 use to your anaesthetist before any procedure or surgery. |
Taking Mounjaro alongside other medications?
Check Mounjaro against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
How does Mounjaro work, and why does that drive the side effects?
Tirzepatide activates both GIP and GLP-1 receptors, producing glucose-dependent insulin release, glucagon suppression, slower gastric emptying, and reduced appetite. The dual mechanism contributes to greater weight loss than GLP-1-only agonists but a similar GI side-effect profile. Slowed gastric emptying is the primary driver of nausea, reflux, and the anaesthetic aspiration concern.
Can you drink alcohol while taking Mounjaro?
Alcohol is not contraindicated, but it can worsen nausea, dehydration, and hypoglycaemia in those also taking insulin or sulfonylureas.
Symptoms and when to seek care
Seek urgent medical assessment if you experience any of the following while taking Mounjaro:
- Severe, persistent abdominal pain (possible pancreatitis)
- Sudden swelling of the face, lips, tongue or throat, or difficulty breathing (allergic reaction)
- Right-upper abdominal pain with fever or jaundice (gallbladder disease)
- Severe vomiting or diarrhoea with reduced urine output (dehydration / kidney injury)
- Severe hypoglycaemia, sweating, confusion, palpitations, loss of consciousness (especially if also on insulin or sulfonylurea)
- New neck mass, hoarseness, or difficulty swallowing (thyroid concern)
- New or worsening depression, mood changes, or suicidal thoughts (Wegovy/Zepbound)
Common Questions About Mounjaro Side Effects
Nausea, diarrhoea, decreased appetite, vomiting, constipation, abdominal pain, usually worst during initiation and dose escalation. Most patients adapt over weeks; persistent or severe symptoms warrant clinical review.
Both carry the same major warnings and have similar serious risks. Head-to-head trial data (SURPASS-2) showed tirzepatide produced greater HbA1c reduction and weight loss than semaglutide 1 mg, with a similar GI side-effect pattern. The right medicine depends on individual factors.
Mounjaro carries an FDA boxed warning for thyroid C-cell tumours, based on rodent data. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Yes, acute pancreatitis has been reported and is a labelled risk. Stop the medicine and seek urgent assessment for severe, persistent abdominal pain that may radiate to the back, especially with vomiting.
Yes, particularly insulin, sulfonylureas (hypoglycaemia risk), oral medicines with narrow therapeutic indices (delayed absorption), and oral contraceptives at Zepbound doses. Use the Allmeds drug interaction checker for a full review.
References
- U.S. Food & Drug Administration. Ozempic (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Wegovy (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Mounjaro (tirzepatide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Zepbound (tirzepatide) prescribing information. fda.gov.
- European Medicines Agency. Ozempic, Wegovy, Mounjaro, EPAR product information. ema.europa.eu.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Check Mounjaro against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.